TET2 and acute myeloid leukemia: Recent cohort studies have shown that about 45% of AML patients are characterized by a normal karyotype [1] and the presence of a few core driver mutations [2] in transcription factors and epigenetic regulators (DNMTs, TET2, ASXL1 and IDH1/2 [3]).